Hu Xinfeng, Tan Congzhu, Zhu Guodong
Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Curr Issues Mol Biol. 2023 May 31;45(6):4763-4777. doi: 10.3390/cimb45060303.
Kidney tumors comprise a broad spectrum of different histopathological entities, with more than 0.4 million newly diagnosed cases each year, mostly in middle-aged and older men. Based on the description of the 2022 World Health Organization (WHO) classification of renal cell carcinoma (RCC), some new categories of tumor types have been added according to their specific molecular typing. However, studies on these types of RCC are still superficial, many types of these RCC currently lack accurate diagnostic standards in the clinic, and treatment protocols are largely consistent with the treatment guidelines for clear cell RCC (ccRCC), which might result in worse treatment outcomes for patients with these types of molecularly defined RCC. In this article, we conduct a narrative review of the literature published in the last 15 years on molecularly defined RCC. The purpose of this review is to summarize the clinical features and the current status of research on the detection and treatment of molecularly defined RCC.
肾肿瘤包括广泛的不同组织病理学实体，每年新诊断病例超过40万，主要发生在中老年男性中。根据2022年世界卫生组织（WHO）肾细胞癌（RCC）分类的描述，根据其特定分子分型增加了一些新的肿瘤类型类别。然而，对这些类型RCC的研究仍然很肤浅，目前这些RCC的许多类型在临床上缺乏准确的诊断标准，并且治疗方案在很大程度上与透明细胞RCC（ccRCC）的治疗指南一致，这可能导致这些分子定义的RCC患者的治疗结果更差。在本文中，我们对过去15年发表的关于分子定义的RCC的文献进行了叙述性综述。本综述的目的是总结分子定义的RCC的临床特征以及检测和治疗的研究现状。
